Positive Contribution of Adjuvanted Influenza Vaccines to the Resolution of Bacterial Superinfections

Journal of Infectious Diseases

Volumn 213, Issue 12, 2016, Pages 1876-1885

  Zurli, Vanessa ^a,b   Gallotta, Marilena ^a,c   Taccone, Marianna ^a   Chiarot, Emiliano ^a   Brazzoli, Michela ^a   Corrente, Federica ^a   Bonci, Alessandra ^a   Casini, Daniele ^a   De Gregorio, Ennio ^a   Baudner, Barbara C ^a   Bertholet, Sylvie ^a   Seubert, Anja ^a  

^a GSK   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Dynavax Technologies Corporation   (United States)

Author keywords

Bacterial superinfection; CpG; Influenza; LTK63; MF59; Staphylococcus aureus; Vaccine adjuvants

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; INFLUENZA VACCINE; INTERLEUKIN 17; INTERLEUKIN 5; LTK 63; MIFAMURTIDE; UNCLASSIFIED DRUG; BACTERIAL TOXIN; ENTEROTOXIN; ESCHERICHIA COLI PROTEIN; HEAT-LABILE ENTEROTOXIN, E COLI; IMMUNOLOGICAL ADJUVANT; MF59 OIL EMULSION; OLIGODEOXYRIBONUCLEOTIDE; POLYSORBATE; SQUALENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL SUPERINFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPOSITION; CELL INFILTRATION; CELL MEDIATED CYTOTOXICITY; CROSS REACTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA A (H1N1); INFLUENZA A VIRUS (H1N1); MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; VACCINATION; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; BAGG ALBINO MOUSE; COMPLICATION; EVALUATION STUDY; GERMFREE ANIMAL; HUMAN; IMMUNOLOGY; INFLUENZA; MICROBIOLOGY; STAPHYLOCOCCUS INFECTION; SUPERINFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL TOXINS; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; POLYSORBATES; SPECIFIC PATHOGEN-FREE ORGANISMS; SQUALENE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SUPERINFECTION;

EID: 84974625999     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw048     Document Type: Article

References (47)

1. WHO. Influenza (seasonal). Fact sheet No. 211. www. who. int/mediacentre/ factsheets/fs211/en/. Accessed 26 October 2015.
2. Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982; 4:25-44.
3. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19:571-82.
4. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol 2014; 12:252-62.
5. Fowlkes AL, Arguin P, Biggerstaff MS, et al. Epidemiology of 2009 pandemic influenza A (H1N1) deaths in the United States, April-July 2009. Clin Infect Dis 2011; 52(suppl 1):S60-8.
6. Centers for Disease C, Prevention. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1)-United States, May-August 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1071-4.
7. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010; 207:2053-63.
8. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198:962-70.
9. McCullers JA, Huber VC. Correlates of vaccine protection from influenza and its complications. Hum Vaccin Immunother 2012; 8:34-44.
10. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359:753-9.
11. Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics 2008; 122:805-11.
12. Center for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56:325-9.
13. Murray RJ, Robinson JO, White JN, et al. Community-acquired pneumonia due to pandemic A(H1N1)2009 influenzavirus and methicillin resistant Staphylococcus aureus co-infection. PLoS One 2010; 5:e8705.
14. Iverson AR, Boyd KL, McAuley JL, Plano LR, Hart ME, McCullers JA. Influenza virus primes mice for pneumonia from Staphylococcus aureus. J Infect Dis 2011; 203:880-8.
15. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of plateletactivating factor receptor. J Infect Dis 2002; 186:341-50.
16. Metzger DW, Sun K. Immune dysfunction and bacterial coinfections following influenza. J Immunol 2013; 191:2047-52.
17. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 2003; 187:1000-9.
18. Plotkowski MC, Puchelle E, Beck G, Jacquot J, Hannoun C. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis 1986; 134:1040-4.
19. Kudva A, Scheller EV, Robinson KM, et al. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol 2011; 186:1666-74.
20. Robinson KM, McHugh KJ, Mandalapu S, et al. Influenza A virus exacerbates Staphylococcus aureus pneumonia in mice by attenuating antimicrobial peptide production. J Infect Dis 2014; 209:865-75.
21. Sun K, Metzger DW. Influenza infection suppresses NADPH oxidase-dependent phagocytic bacterial clearance and enhances susceptibility to secondary methicillin-resistant Staphylococcus aureus infection. J Immunol 2014; 192:3301-7.
22. Small CL, Shaler CR, McCormick S, et al. Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung. J Immunol 2010; 184:2048-56.
23. Shahangian A, Chow EK, Tian X, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 2009; 119:1910-20.
24. Baudner BC, Ronconi V, Casini D, et al. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res 2009; 26:1477-85.
25. Gallorini S, Taccone M, Bonci A, et al. Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses. Vaccine 2014; 32:2382-8.
26. Kommareddy S, Bonificio A, Gallorini S, Baudner B, Singh M, O'Hagan D. Preparation of highly concentrated influenza vaccine for use in novel delivery approaches. J Pharm Sci 2013; 102:866-75.
27. Calabro S, Tortoli M, Baudner BC, et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011; 29:1812-23.
28. GiulianiMM, Del Giudice G, Giannelli V, et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novelmutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 1998; 187:1123-32.
29. Brazzoli M, Magini D, Bonci A, et al. Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. J Virol 2015; 90:332-44.
30. Huber VC, Thomas PG, McCullers JA. A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine 2009; 27:1192-200.
31. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res 2011; 162:19-30.
32. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+ T cells in immunity to viruses. Nat Rev Immunol 2012; 12:136-48.
33. Cox RJ. Correlates of protection to influenza virus, where do we go from here? Hum Vaccin Immunother 2013; 9:405-8.
34. Food and Drug Administration. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. http://www. fda. gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ Guidances/Vaccines/ucm074794. htm. Accessed 26 October 2015.
35. Flannery B, Clippard J, Zimmerman RK, et al. Early estimates of seasonal influenza vaccine effectiveness-United States, January 2015. MMWRMorb Mortal Wkly Rep 2015; 64:10-5.
36. D'Mello T, Brammer L, Blanton L, et al. Update: Influenza activity-United States, September 28, 2014-February 21, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:206-12.
37. Narasaraju T, Yang E, Samy RP, et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J Pathol 2011; 179:199-210.
38. Damjanovic D, Lai R, Jeyanathan M, Hogaboam CM, Xing Z. Marked improvement of severe lung immunopathology by influenza-associated pneumococcal superinfection requires the control of both bacterial replication and host immune responses. Am J Pathol 2013; 183:868-80.
39. Smith AM, Adler FR, Ribeiro RM, et al. Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog 2013; 9:e1003238.
40. Nunes A, Nogueira PJ, Borrego MJ, Gomes JP. Adaptive evolution of the Chlamydia trachomatis dominant antigen reveals distinct evolutionary scenarios for B- and T-cell epitopes: worldwide survey. PLoS One 2010; 5:e13171.
41. Sun K, Ye J, Perez DR, Metzger DW. Seasonal FluMist vaccination induces crossreactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J Immunol 2011; 186:987-93.
42. Tsai TF. Fluad®-MF59®-adjuvanted influenza vaccine in older adults. Infect Chemother 2013; 45:159-74.
43. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59-an innately attractive adjuvant formulation. Vaccine 2012; 30:4341-8.
44. Del Giudice G, Rappuoli R. Inactivated and adjuvanted influenza vaccines. Curr Top Microbiol Immunol 2015; 386:151-80.
45. Mouton CP, Bazaldua OV, Pierce B, Espino DV. Common infections in older adults. Am Fam Physician 2001; 63:257-68.
46. La Gruta NL, Turner SJ. T cell mediated immunity to influenza: mechanisms of viral control. Trends Immunol 2014; 35:396-402.
47. Settembre EC, Dormitzer PR, Rappuoli R. Bringing influenza vaccines into the 21st century. Hum Vaccin Immunother 2014; 10:600-4.